Welcome to our dedicated page for Nexgel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on Nexgel stock.
NexGel, Inc. develops and commercializes healthcare, beauty and over-the-counter products built around high-water-content hydrogel technology for healthcare and consumer applications.
Company news commonly covers operating and financial results, hydrogel and biomaterial product activity, strategic partnerships, acquisition and licensing activity, financing arrangements, and governance changes. Recent updates also document the launch of BioNX Surgical following a completed license and asset acquisition of commercial-stage regenerative biomaterial products.
NEXGEL (NASDAQ:NXGL) announced a leadership transition and a broad strategic review aimed at strengthening liquidity, operational execution and long-term shareholder value. Effective August 21, 2026, Brian Kieser is appointed Interim CEO, following his role in integrating the BioNX Surgical division and related strategic initiatives.
The Board formed a Special Committee for Strategic Review and Value Creation, comprising Kevin Harris (Chair) and Steve Glassman, to assess operations, non-core assets, capital structure, and restructuring options, with an initial framework expected in 30–45 days. CEO Adam Levy will leave his roles on August 21, 2026, but provide 90 days of transition assistance. The Board highlights BioNX Surgical, BioNX Regenerative Eye Health & Aesthetics, and advanced hydrogel technologies as key growth platforms.
NEXGEL (NASDAQ:NXGL) reported second quarter 2026 revenue of $3.69 million and a net loss of $2.87 million for the period ended June 30, 2026. The quarter reflected integration of the April Celularity transaction, formation of the BioNX Surgical division, and preparation for broader commercial rollout.
According to the company, ongoing supply chain constraints at Celularity’s New Jersey facility contributed to a BioNX Surgical order backlog of approximately $795,000, despite deployment of Sequence Life Science specialists to support technology transfer to San Antonio. The loss included $756,554 of BioNX intangible amortization, $273,710 of one-time transaction expenses, and $144,495 tied to a strategic recall of SilverSeal inventory from Amazon ahead of an August hospital-market launch. NEXGEL also introduced the BioNX Regenerative Eye Health & Aesthetics platform, saw the release of about $710,000 in previously restricted cash post‑quarter, and plans to re‑solicit shareholder approval for an authorized share increase and reverse split, targeting completion in late September and an investor update call around September 15, 2026.
NEXGEL (NASDAQ:NXGL) announced that CEO Adam Levy will present at the Planet MicroCap Conference in Las Vegas from June 16–18, 2026 at the Bellagio Hotel & Casino.
Levy’s presentation is scheduled for Wednesday, June 17, 2026 at 1:30 p.m. PT in Track 3 - Da Vinci 3, with a webcast available via the company’s investor relations site. Investors can also schedule one-on-one meetings by contacting KCSA Strategic Communications at the provided email.
NEXGEL (NASDAQ:NXGL) reported positive data from a randomized, 30-patient, single-center IRB study of its hydrogel laser treatment patch used in laser hair removal.
The patch achieved a 95.6% reduction in laser plume concentration versus control, lower mean pain scores (3.5 vs. 5.1), and numerically greater hair reduction (37.2% vs. 26.7%) at 90 days, with no adverse events. Results were published in Lasers in Surgery and Medicine in 2026.
NEXGEL (NASDAQ:NXGL) appointed Dave Hazard as Vice President of Sales for its BIONX Surgical division, effective May 13, 2026. The role supports commercialization of the newly launched division formed through a transformative acquisition expected to scale revenue.
Hazard brings extensive orthopedic, spine, and biologics sales leadership experience and prior partnerships relevant to BIONX Surgical.
NEXGEL (NASDAQ:NXGL) will report first quarter 2026 financial results for the period ended March 31, 2026 on Friday, May 15, 2026.
Management will host a conference call at 12:00 P.M. ET, with phone and webcast access plus replay options.
NEXGEL (NASDAQ: NXGL) appointed Brian J. Kieser, CPA and Kevin Harris, CFA from strategic partner Sequence LifeScience to its Board of Directors on May 6, 2026.
Sequence LifeScience led financing to close the acquisition of Celularity's degenerative disease segment with a $5.5 million strategic investment; management highlights partnership, industry experience, product innovation, and distribution support.
NEXGEL (NASDAQ:NXGL) named Ian Blackman, CPA, as Chief Financial Officer effective April 27, 2026. Mr. Blackman will support closing and integration of a definitive agreement to license and acquire commercial-stage regenerative biomaterial products from Celularity and scale NEXGEL’s consumer and healthcare businesses.
He brings over 30 years of finance and M&A experience, prior CFO roles in luxury consumer companies, and a record of revenue and EBITDA expansion in prior positions.
NEXGEL (NASDAQ: NXGL) closed the license and acquisition of Celularity's commercial-stage regenerative biomaterials portfolio and launched BioNX Surgical. The deal is led by a $5.5 million strategic investment from Sequence LifeScience™ and financed via a convertible note with a $0.60 conversion price and 50% warrant coverage. The transaction is expected to approximately triple pro-forma annual revenue to about $35 million and be immediately accretive to profitability, adding 6 established products with existing reimbursement and accelerating commercialization.
NEXGEL (NASDAQ:NXGL) moved its shareholder update conference call to April 21, 2026 at 4:30 P.M. ET to discuss the Celularity transaction. Investors can join via U.S. toll-free 1-800-267-6316, international 1-203-518-9783, or the company webcast under Events and Presentations.